Collins Susan E, Saxon Andrew J, Duncan Mark H, Smart Brian F, Merrill Joseph O, Malone Daniel K, Jackson T Ron, Clifasefi Seema L, Joesch Jutta, Ries Richard K
Department of Psychiatry and Behavioral Sciences, University of Washington - Harborview Medical Center, 325 Ninth Ave Box 359911, Seattle, WA 98195, USA.
VA Puget Sound Health Care System, 1660 S. Columbian Way, Seattle, WA 98108, USA; Department of Psychiatry and Behavioral Sciences, University of Washington, 1100 45th St. Box 354944, Seattle, WA 98195, USA.
Contemp Clin Trials. 2014 Jul;38(2):221-34. doi: 10.1016/j.cct.2014.05.008. Epub 2014 May 17.
Interventions requiring abstinence from alcohol are neither preferred by nor shown to be highly effective with many homeless individuals with alcohol dependence. It is therefore important to develop lower-threshold, patient-centered interventions for this multimorbid and high-utilizing population. Harm-reduction counseling requires neither abstinence nor use reduction and pairs a compassionate style with patient-driven goal-setting. Extended-release naltrexone (XR-NTX), a monthly injectable formulation of an opioid receptor antagonist, reduces craving and may support achievement of harm-reduction goals. Together, harm-reduction counseling and XR-NTX may support alcohol harm reduction and quality-of-life improvement.
Study aims include testing: a) the relative efficacy of XR-NTX and harm-reduction counseling compared to a community-based, supportive-services-as-usual control, b) theory-based mediators of treatment effects, and c) treatment effects on publicly funded service costs.
This RCT involves four arms: a) XR-NTX+harm-reduction counseling, b) placebo+harm-reduction counseling, c) harm-reduction counseling only, and d) community-based, supportive-services-as-usual control conditions. Participants are currently/formerly homeless, alcohol dependent individuals (N=300). Outcomes include alcohol variables (i.e., craving, quantity/frequency, problems and biomarkers), health-related quality of life, and publicly funded service utilization and associated costs. Mediators include 10-point motivation rulers and the Penn Alcohol Craving Scale. XR-NTX and harm-reduction counseling are administered every 4weeks over the 12-week treatment course. Follow-up assessments are conducted at weeks 24 and 36.
If found efficacious, XR-NTX and harm-reduction counseling will be well-positioned to support reductions in alcohol-related harm, decreases in costs associated with publicly funded service utilization, and increases in quality of life among homeless, alcohol-dependent individuals.
对于许多酒精依赖的无家可归者而言,要求戒酒的干预措施既不受他们青睐,效果也未被证明十分显著。因此,为这个患有多种疾病且高医疗利用率的人群开发低门槛、以患者为中心的干预措施非常重要。减少伤害咨询既不要求戒酒也不要求减少饮酒量,而是将富有同情心的方式与患者驱动的目标设定相结合。长效纳曲酮(XR-NTX)是一种每月注射一次的阿片受体拮抗剂,可减少渴望,并可能有助于实现减少伤害的目标。减少伤害咨询和XR-NTX共同作用,可能有助于减少酒精危害并改善生活质量。
研究目的包括测试:a)与基于社区的常规支持性服务对照相比,XR-NTX和减少伤害咨询的相对疗效;b)基于理论的治疗效果中介因素;c)治疗对公共资助服务成本的影响。
这项随机对照试验包括四个组:a)XR-NTX+减少伤害咨询;b)安慰剂+减少伤害咨询;c)仅减少伤害咨询;d)基于社区的常规支持性服务对照。参与者为目前或曾经无家可归、酒精依赖的个体(N=300)。结果包括酒精相关变量(即渴望、饮酒量/频率、问题和生物标志物)、健康相关生活质量以及公共资助服务的使用情况和相关成本。中介因素包括10分制动机量表和宾夕法尼亚酒精渴望量表。在为期12周的治疗过程中,每4周进行一次XR-NTX和减少伤害咨询。在第24周和第36周进行随访评估。
如果被证明有效,XR-NTX和减少伤害咨询将有望支持减少与酒精相关的危害、降低公共资助服务使用相关的成本,并提高无家可归、酒精依赖个体的生活质量。